Applications Claiming H5 or N1 or Both
For these applications, PAIR on the USPTO web site was consulted to determine which nucleotide sequences are currently pending. The applications shown in the table below all claim an H5 and/or an N1 segment. The MedImmune patent application is directed to a live virus that would raise immunity to H5N1, but which does not cause disease itself. If these claims are granted (as seems likely), the claims are not very broad; claim 17 requires specific sequences or origins of seven of the genome segments. The two WARF patent applications are drawn to a similar type of virus to raise immunity to H1N1.
The last column shows the non U.S. jurisdictions where related patent applications are filed. No information is provided here regarding the status of these applications.
Of the 4 applications in the table below, 3 are assigned to non-profit organizations and one is assigned to a corporation.
|
Application No. |
Assignee |
Title |
Sequences Currently Pending and Corresponding Segment |
Status |
Other Jurisdictions with Family Members |
|---|---|---|---|---|---|
|
MedImmune Vaccines, Inc. |
Influenza hemagglutinin and neuraminidase variants |
5 - segment 4 (encoding H5) 6 - segment 6 (encoding N1) |
Pending; Final Rejection Mailed Cl 17: A reassortment virus, with 6 internal genome segments from influenza
strain Cl 24: An immunogenic amount of reassortment virus further comprising a nucleic acid encoding NA selected from ID 12, 14, 16, 18 and 20. Related application US 2005-0287172 has similar claim to claim 17, but drawn to NA having amino acid sequence of SEQ ID NO: 16 and SEQ ID NO: 5 encoding HA. |
Australia, Canada, Europe, Japan |
|
|
National Tsing Hua University |
Pseudotyped baculovirus to stimulate immunogenicity against avian influenza |
2 - segment 4 encoding H5 |
Pending; Ready for Examination Claims are directed to vectors that encode viral proteins, including H5. |
- |
|
|
Wisconsin Alumni Research Foundation (WARF) |
High titer recombinant influenza viruses for vaccines and gene therapy |
3
- segment
1 |
Pending; Final Action Mailed Cl 8: High titre reassortment virus comprising plurailty of vectors for vRNA production and vectors for mRNA production. |
Australia, Brazil, Canada, China, Europe, Japan, Korea, Norway, South Africa |
|
|
Wisconsin Alumni Research Foundation |
High titer recombinant influenza viruses for vaccines |
3
- segment
1 |
Pending; Restriction requirement mailed (response due 2008.05.28) Claims are directed to vectors that produce a 7:1 reassortment virus. |
World |
The information contained in this page was believed to be correct at the time it was collated. New patents and patent applications, altered status of patents, and case law may have resulted in changes in the landscape. CAMBIA makes no warranty that it is correct or up to date at this time and accepts no liability for any use that might be made of it. Corrections or updates to the information are welcome. Please send an email to info@bios.net.
There are no comments.